Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option

E-ISSN： 1742-1241|69|12|1427-1437

ISSN： 1368-5031

Source： INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol.69, Iss.12, 2015-12, pp. : 1427-1437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A double-blind, randomised, crossover study of two doses of a single-tablet combination of ibuprofen/paracetamol and placebo for primary dysmenorrhoea

By Eccles Ronald Holbrook Amanda Jawad Martez

Current Medical Research and Opinion, Vol. 26, Iss. 11, 2010-11 ,pp. : 2689-2699

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 946-954

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 299-301

John Wiley & Sons Inc

Access to resources Recommend Favorite

Voxelotor (GBT440), a first‐in‐class hemoglobin oxygen‐affinity modulator, has promising and reassuring preclinical and clinical data

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 326-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First‐in‐Class Mirror‐Image Oligonucleotide Inhibitor of CXCL12

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 1, 2013-07 ,pp. : 150-157

John Wiley & Sons Inc

Access to resources Recommend Favorite